Gut and Liver. 2023 Jan; 17(1): 8419365. doi: 10.5009/gnl220041
Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
Wolhwa Song , Sung Hwan Yoo , Jinsun Jang , Su Jung Baik , Byoung Kwon Lee , Hyun Woong Lee* , Jong Suk Park*
expand
-
-
원문보기
-
조회
상세조회 10건
-
-
Abstract
Background/Aims : There are no data regarding the association between sarcopenic obesity status and nonalcoholic fatty liver disease (NAFLD) and NAFLD-associated liver fibrosis. Therefore, we aimed to investigate the relationship between sarcopenic obesity status (sarcopenia only, obesity only, and sarcopenic obesity) and NAFLD and liver fibrosis in Korean adults.
Methods : In total, 2,191 subjects completed a health checkup program, including abdominal ultrasonography and FibroScan. Subjects were classified into the following four categories: optimal body composition (nonobese and nonsarcopenic), sarcopenia only (nonobese), obesity only (nonsarcopenic), and sarcopenic obesity. Sarcopenic obesity was stratified by the skeletal muscle mass index and body fat using bioelectrical impedance analysis. NAFLD was diagnosed by ultrasonography, and liver fibrosis was assessed using transient elastography in subjects with NAFLD.
Results : The prevalence of NAFLD and liver fibrosis significantly increased according to the sarcopenic obesity status. In the logistic regression analysis, after adjusting for multiple risk factors, the odds ratio (OR) for the risk of NAFLD was largest in the sarcopenic obesity group (OR, 3.68; 95% confidence interval [CI], 2.94 to 4.60), followed by the obesity only (OR, 2.25; 95% CI, 1.67 to 3.03) and sarcopenia only (OR, 1.92; 95% CI, 1.30 to 2.84) groups, when compared with the optimal group. Additionally, liver fibrosis was independently associated with sarcopenic obesity status (OR 4.69, 95% CI 1.95 to 11.29; OR 4.17, 95% CI 1.56 to 11.17; OR 3.80, 95% CI 0.86 to 16.75, respectively).
Conclusions : These results demonstrated that sarcopenic obesity was independently associated with NAFLD and liver fibrosis and increased the risk of NAFLD and liver fibrosis more than obesity or sarcopenia alone. -
Keywords
-
MeSH Term
-
References
more references
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L,Wymer M. Global epidemiology of nonalcoholic fatty liverdisease: meta-analytic assessment of prevalence, incidence,and outcomes. Hepatology 2016;64:73-84.
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis andmanagement of nonalcoholic fatty liver disease: practiceguidance from the American Association for the Study ofLiver Diseases. Hepatology 2018;67:328-357.
3. Angulo P. Obesity and nonalcoholic fatty liver disease. NutrRev 2007;65(6 Pt 2):S57-S63.
4. Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-subcutaneous abdominal fat ratio is associated withnonalcoholic fatty liver disease and liver fibrosis. EndocrinolMetab (Seoul) 2020;35:165-176.
5. Lee MK, Rhee EJ, Kim MC, et al. Metabolic health is moreimportant than obesity in the development of nonalcoholicfatty liver disease: a 4-year retrospective study. EndocrinolMetab (Seoul) 2015;30:522-530.
6. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults: current consensusdefinition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc2011;12:249-256.
7. Kim TN, Choi KM. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J Cell Biochem2015;116:1171-1178.
8. Issa D, Alkhouri N, Tsien C, et al. Presence of sarcopenia(muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology 2014;60:428-429.
9. Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Associationbetween sarcopenic obesity and nonalcoholic fatty liverdisease and fibrosis detected by Fibroscan. J GastrointestinLiver Dis 2021;30:227-232.